<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="11">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 22, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02207088</url>
  </required_header>
  <id_info>
    <org_study_id>M14-226</org_study_id>
    <secondary_id>2014-001527-77</secondary_id>
    <nct_id>NCT02207088</nct_id>
  </id_info>
  <brief_title>Ombitasvir/ABT-450/Ritonavir and Dasabuvir With or Without Ribavirin in HCV Genotype 1-Infected Adults With Chronic Kidney Disease</brief_title>
  <official_title>An Open-Label Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection, With Severe Renal Impairment or End-Stage Renal Disease (RUBY-I)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This open-label study will evaluate safety, pharmacokinetics and efficacy of a 12 or 24 week
      regimen of ombitasvir/paritaprevir/ritonavir and dasabuvir with or without ribavirin in
      HCV-genotype 1-infected subjects with an Estimated Glomerular Filtration Rate (eGFR) &lt;30,
      including those on hemodialysis or peritoneal dialysis.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2014</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Percentage of subjects with Sustained Virologic Response 12 weeks post-treatment</measure>
    <time_frame>12 Weeks after the last actual dose of study drug</time_frame>
    <safety_issue>No</safety_issue>
    <description>HCV RNA less than the lower limit of quantification.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with on-treatment virologic failure</measure>
    <time_frame>Up to 12 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>The percentage of subjects with confirmed, quantifiable HCV RNA among subjects with previous unquantifiable HCV RNA during treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with post-treatment relapse</measure>
    <time_frame>Within 12 weeks after the last dose of study drug</time_frame>
    <safety_issue>No</safety_issue>
    <description>The percentage of subjects with confirmed, quantifiable HCV RNA between the end of treatment and 12 weeks after the last dose of study drug among subjects completing treatment and with unquantifiable HCV RNA at the end of treatment.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Chronic Hepatitis C</condition>
  <condition>Hepatitis C Virus</condition>
  <condition>Compensated Cirrhosis</condition>
  <condition>Severe Renal Impairment</condition>
  <condition>End-stage Renal Disease</condition>
  <arm_group>
    <arm_group_label>3 DAA (Direct Acting Antivirals) with or without RBV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Genotype 1a or 1b infected, treatment-naive or IFN treatment experienced subjects with renal impairment, with or without cirrhosis</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ombitasvir/paritaprevir/ritonavir</intervention_name>
    <description>tablet</description>
    <arm_group_label>3 DAA (Direct Acting Antivirals) with or without RBV</arm_group_label>
    <other_name>ABT-450/r/ABT-267</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dasabuvir</intervention_name>
    <description>tablet</description>
    <arm_group_label>3 DAA (Direct Acting Antivirals) with or without RBV</arm_group_label>
    <other_name>ABT-333</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin</intervention_name>
    <description>tablet</description>
    <arm_group_label>3 DAA (Direct Acting Antivirals) with or without RBV</arm_group_label>
    <other_name>RBV</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Positive for anti-HCV Ab (Antibody) and HCV RNA &gt;1,000 IU/mL at Screening.

          2. Screening laboratory result indicating HCV genotype 1 infection.

          3. Subject has never received antiviral treatment for hepatitis C infection
             (treatment-naive subject) or subject has received previous treatment with
             peginterferon with or without RBV with non-response (HCV RNA quantifiable at end of
             treatment or relapsed after end of treatment).

          4. Estimated Glomerular Filtration Rate (eGFR) &lt; 30 mL/min/1.73 m^2 as estimated by the
             Modification of Diet in Renal Disease (MDRD) method.

        Exclusion Criteria:

          1. Women who are pregnant or breastfeeding.

          2. Positive test result for Hepatitis B surface antigen (HBsAg) or anti-Human
             Immunodeficiency Virus (HIV Ab).

          3. Any current or past clinical evidence of Child-Pugh B or C classification or clinical
             history of liver decompensation such as ascites (noted on physical exam), variceal
             bleeding, or hepatic encephalopathy.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric Cohen, MD</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christi Kosogof, BS</last_name>
    <phone>847-937-7481</phone>
    <email>christi.kosogof@abbvie.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Melissa Jewett, BS</last_name>
    <phone>919-403-5881</phone>
    <email>melissa.jewett@abbvie.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 128226</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85054</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 128226, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 141426</name>
      <address>
        <city>Coronado</city>
        <state>California</state>
        <zip>92118</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 141426, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 128225</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 128225, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 127548</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 127548, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 128227</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 128227, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 127554</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610-0272</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 127554, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 141790</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33548</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 141790, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 127557</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 127557, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 127549</name>
      <address>
        <city>Manhasset</city>
        <state>New York</state>
        <zip>11030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 127549, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 141791</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 141791, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 140975</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 140975</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 127555</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 127555, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 127553</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 127553, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 127558</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 127558, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 127552</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 127552, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 141427</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 141427, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <lastchanged_date>October 16, 2015</lastchanged_date>
  <firstreceived_date>July 31, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Compensated Cirrhosis</keyword>
  <keyword>dialysis</keyword>
  <keyword>Hepatitis C Virus</keyword>
  <keyword>Severe Renal Impairment</keyword>
  <keyword>Renal impairment</keyword>
  <keyword>cirrhosis</keyword>
  <keyword>Chronic Hepatitis C</keyword>
  <keyword>Hepatitis C</keyword>
  <keyword>End-stage renal disease</keyword>
  <keyword>Hepatitis C Genotype 1</keyword>
  <keyword>renal disease</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Ritonavir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
